Literature DB >> 3356364

Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro.

K J Goerg1, R Wanitschke, P H Diehl, K H Meyer zum Büschenfelde.   

Abstract

Azodisalicylate (ADS) is one of the newly developed substitutes of sulphasalazine consisting of two molecules of 5-amino-salicylic acid. Azodisalicylate caused diarrhoea in some patients, apparently caused by an antiabsorptive secretagogue action of this compound. The mechanism of this was studied in the short circuited isolated mucosa of the rat ileum. Mucosal addition of ADS increased the potential difference (PD) and short circuit current (Isc) at a concentration of 1.3.10(-4) mol/l (4 mg/dl) with maximal effects at 1.3.10(-3) mol/l (40 mg/dl). Epithelial resistance was only slightly decreased at the higher concentrations of 40 and 100 mg/dl. Serosal ADS had no effect on electrical parameters. The increase of Isc was associated with a change of net chloride absorption into net secretion. Net sodium absorption was only slightly and not significantly decreased. The changes were reversible after rinsing away the ADS. Treatment of the mucosa with furosemide inhibited the ADS induced increase of Isc, suggesting transcellular pathway for the ADS stimulated secretion. Biosynthesis of prostaglandins is not involved in the mechanism of this secretion, as treatment with indomethacin did not alter the effect of ADS on Isc. Results suggest that ADS can be considered as a secretagogue, which stimulates intestinal secretion via a transcellular pathway. Because of the bacterial cleavage of the double molecule into two molecules of the non-secretagogue 5-amino-salicylic acid in the colon, however, diarrhoea may develop only in patients with a decreased absorptive capacity of the colon, or insufficient cleavage of ADS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356364      PMCID: PMC1433612          DOI: 10.1136/gut.29.3.336

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Will there be a next generation of sulfasalazine?

Authors:  P Goldman
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

2.  Desensitization of patients with inflammatory bowel disease to sulfasalazine.

Authors:  S L Taffet; K M Das
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

3.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

4.  Sodium-dependent chloride secretion across rabbit descending colon.

Authors:  K Heintze; C P Stewart; R A Frizzell
Journal:  Am J Physiol       Date:  1983-04

5.  Saturation kinetics applied to in vitro effects of low prostaglandin E2 and F 2 alpha concentrations on ion transport across human jejunal mucosa.

Authors:  K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1980-01       Impact factor: 22.682

6.  Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).

Authors:  P A van Hees; J H Tuinte; J M van Rossum; J H van Tongeren
Journal:  Gut       Date:  1979-04       Impact factor: 23.059

7.  Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy.

Authors:  H Sandberg-Gertzén; M Ryde; G Järnerot
Journal:  Scand J Gastroenterol       Date:  1983-01       Impact factor: 2.423

8.  Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.

Authors:  K Lauritsen; J Hansen; M Ryde; J Rask-Madsen
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

9.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

10.  Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.

Authors:  R A van Hogezand; P A van Hees; B Zwanenburg; J M van Rossum; J H van Tongeren
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

View more
  4 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 3.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

Authors:  S Kiilerich; K Ladefoged; T Rannem; P J Ranløv
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.